Post transplant administration of AMD3100 increases CFUs-spleen and reduces cytokine, chemokine, and growth factor levels.

<p>A: CFUs-spleen assay. Lethally irradiated CD45.2 mice (10.5 Gy) were injected with whole marrow cells from CD45.1 mice (1×10⁵ marrow cells per mouse). The recipient mice were injected subcutaneously with PBS buffer or AMD3100 at 5 mg/kg every other day beginning at day +2. At day +9, the mice were sacrificed and CFUs-spleen measured (n = 5–10 mice per group). B: Plasma cytokine/chemokine measurement. Lethally irradiated CD45.2 mice (10.5 Gy) were injected with sorted KTLS stem cell from CD45.1 mice (7000 KTLS cells per mouse). The recipient mice were injected subcutaneously with PBS buffer or AMD3100 at 5 mg/kg every other day beginning at day +2. The mice were bled at Day +7 and plasma prepared. Plasma cytokines and chemokines (pg/ml) were measured as per manufacturer's instruction (Bioplex, Bio-Rad Laboratories) (n = 5 mice per group). G-CSF level was shown in a separate panel. C: 9 cytokines/chemokines that were significantly reduced in AMD3100-treated mice. D: Survival rate in lethally irradiated mice without HCT. CD45.2 mice were lethally irradiated (10.5 Gy) but not transplanted with HSCs. The mice were then administered subcutaneously with PBS or AMD3100 at 5 mg/kg every other day beginning at day +2 post irradiation until the end of experiments. Animal survival was monitored daily (data representative of 3 separate sets of experiments with 10 mice in each group of each experiment).